Effect of Ginger consumption on the Clinical Manifestation and Blood Pressure in adult with Rheumatoid Arthritis

The effect of ginger consumption on the Clinical Manifestation and Blood Pressure in adult with Active Rheumatoid Arthritis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201206179472N3

Enrollment

Registered

2012-09-29

Start date

2012-10-01

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adult with Active Rheumatoid Arthritis. Other specified Rheumatoid Arthritis

Interventions

Intervention 1: taking Ginger supplement, 1600 miligram (2* 800 milligrams capsules ginger powder per day. during 3 months (12 weeks). Intervention 2: taking Placebo, 1600 miligram (2* 800 milligrams

Treatment - Other

Placebo

taking Ginger supplement, 1600 miligram (2* 800 milligrams capsules ginger powder per day. during 3 months (12 weeks)

taking Placebo, 1600 miligram (2* 800 milligrams capsules) Starch powder per day during 3 months (12 weeks).

Eligibility

Sex/Gender

All

Age

20 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: person with RA diaseases as ACR criteria; having RA from 2 years ago; age between 20-69 years; not being pregnant or lactated; not smoking and drink alcoho; havn't eaten multivitamin or antioxidants supplements from 3 month ago; don't eat lowering blood pressure; don't eat anti pregnancy drugs; exclusion criteria; Changes in diet or physical activity every day; taking less than 80% of supplements given to patients at baseline(the compaliance lower than %80); consumption of contraceptives; multivitamins and antioxidant supplements; renal, hepatic,thyroid, parathyroid diseases, cancer and heart diseases.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Pain. Timepoint: Before and after intervention. Method of measurement: Visual analogue scales.;Number of inflammated joints. Timepoint: Before and after intervention. Method of measurement: Examintion.;Morning stiffness. Timepoint: Before and after intervention. Method of measurement: Examintion.;Global physician assesment. Timepoint: Before and after intervention. Method of measurement: Examintion.;Sistolic Blood pressure. Timepoint: Before and after intervention. Method of measurement: Sphygmomanometer.;Distolic Blood pressurs. Timepoint: Before and after intervention. Method of measurement: Sphygmomanometer.	—

Measure

Time frame

Pain. Timepoint: Before and after intervention. Method of measurement: Visual analogue scales.;Number of inflammated joints. Timepoint: Before and after intervention. Method of measurement: Examintion.;Morning stiffness. Timepoint: Before and after intervention. Method of measurement: Examintion.;Global physician assesment. Timepoint: Before and after intervention. Method of measurement: Examintion.;Sistolic Blood pressure. Timepoint: Before and after intervention. Method of measurement: Sphygmomanometer.;Distolic Blood pressurs. Timepoint: Before and after intervention. Method of measurement: Sphygmomanometer.

—

Secondary

Measure	Time frame
BMI. Timepoint: Before and after intervention. Method of measurement: weight/height^2.;Waist Circumference. Timepoint: Before and after study. Method of measurement: Tape.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNaheed Aryaeian

Tums(Tehran University of Medical Sciences)

n-aryaeian@sina.tums.ac.ir+98 21 8877 7674

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026